Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue: 2023-2024
Historic Non-Current Deffered Revenue for Ascentage Pharma Group International (AAPG) over the last 2 years, with Dec 2024 value amounting to $34.0 million.
- Ascentage Pharma Group International's Non-Current Deffered Revenue fell 2.43% to $34.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $34.0 million, marking a year-over-year decrease of 2.43%. This contributed to the annual value of $34.0 million for FY2024, which is 4.23% down from last year.
- Per Ascentage Pharma Group International's latest filing, its Non-Current Deffered Revenue stood at $34.0 million for FY2024, which was down 4.23% from $35.5 million recorded in FY2023.
- Over the past 5 years, Ascentage Pharma Group International's Non-Current Deffered Revenue peaked at $35.5 million during FY2023, and registered a low of $34.0 million during FY2024.
- Over the past 2 years, Ascentage Pharma Group International's median Non-Current Deffered Revenue value was $34.8 million (recorded in 2023), while the average stood at $34.8 million.
- Data for Ascentage Pharma Group International's Non-Current Deffered Revenue shows a maximum YoY decreased of 4.23% (in 2024) over the last 5 years.
- Ascentage Pharma Group International's Non-Current Deffered Revenue (Yearly) stood at $35.5 million in 2023, then declined by 4.23% to $34.0 million in 2024.